Manohar Mahadev
Manohar Mahadev has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Akhilesh Dubey
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India
4 shared publications - Amitha Shetty
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore 575018, India
3 shared publications - Mohammed Arfath Mysore Ismail
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India
3 shared publications - Mahendra Gowdru Srinivasa
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Mangalore-575018, India
2 shared publications - Akhil Nair
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Mangaluru 575018, India
1 shared publication Akhilesh Dubey
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 156-170
Chitosan-Coated Nanoemulsion for Quercetin Delivery: Formulation Optimisation and Pharmacokinetic Evaluation
Objective: The present study aimed to develop a chitosan-coated quercetin nanoemulsion (CS-QCT-NE) and to assess its pharmacokinetic performance following oral administration. Methods: A nanoemulsion was formulated using oleic acid as the oil phase, Tween-20 as surfactant, and PEG-200 as cosurfactant. A rotatable central composite design (CCD) with an α value of 1.414 was employed to optimise the nanoemulsion formulation by investigating the influence of organic phase concentration (30-50%), sonication amplitude (20-24%), and sonication time (0-160 s) on globule size (GS), polydispersity index (PDI), and entrapment efficiency (EE). The selected QCT-NE was subsequently coated with low-and medium-molecular-weight chitosan at concentrations of 0.5%, 1.0%, and 1.5% for comparative evaluation, and the 1.5% LMW-coated formulation was empirically selected for further characterisation. It was analysed using transmission electron microscopy (TEM), in vitro drug release testing, and pharmacokinetic and biodistribution studies. Results: The selected CS-QCT-NE exhibited a globule size of 135.4±2.39 nm, PDI of 0.254±0.001, and zeta potential of+26.8±5.97 mV. TEM analysis confirmed spherical droplets with a uniform size distribution. In vitro drug release studies showed 83.72% cumulative drug release in pH 7.4 phosphate buffer within 48 h. Pharmacokinetic assessment showed approximately a 2.43-fold higher systemic exposure, as indicated by AUC0-24, for CS-QCT-NE compared with QCT-PD, corresponding to an exploratory relative oral exposure of 242.8%. Conclusion: The 1.5% LMW chitosan-coated nanoemulsion resulted in higher systemic quercetin (QCT) exposure following oral administration. These pharmacokinetic results are preliminary, and additional studies with a fully validated bioanalytical method are necessary to verify the observed differences.
- 7 November 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 156-170
Open AccessChitosan-Coated Nanoemulsion for Quercetin Delivery: Formulation Optimisation and Pharmacokinetic Evaluation
Objective: The present study aimed to develop a chitosan-coated quercetin nanoemulsion (CS-QCT-NE) and to assess its pharmacokinetic performance following oral administration. Methods: A nanoemulsion was formulated using oleic acid as the oil phase, Tween-20 as surfactant, and PEG-200 as cosurfactant. A rotatable central composite design (CCD) with an α value of 1.414 was employed to optimise the nanoemulsion formulation by investigating the influence of organic phase concentration (30-50%), sonication amplitude (20-24%), and sonication time (0-160 s) on globule size (GS), polydispersity index (PDI), and entrapment efficiency (EE). The selected QCT-NE was subsequently coated with low-and medium-molecular-weight chitosan at concentrations of 0.5%, 1.0%, and 1.5% for comparative evaluation, and the 1.5% LMW-coated formulation was empirically selected for further characterisation. It was analysed using transmission electron microscopy (TEM), in vitro drug release testing, and pharmacokinetic and biodistribution studies. Results: The selected CS-QCT-NE exhibited a globule size of 135.4±2.39 nm, PDI of 0.254±0.001, and zeta potential of+26.8±5.97 mV. TEM analysis confirmed spherical droplets with a uniform size distribution. In vitro drug release studies showed 83.72% cumulative drug release in pH 7.4 phosphate buffer within 48 h. Pharmacokinetic assessment showed approximately a 2.43-fold higher systemic exposure, as indicated by AUC0-24, for CS-QCT-NE compared with QCT-PD, corresponding to an exploratory relative oral exposure of 242.8%. Conclusion: The 1.5% LMW chitosan-coated nanoemulsion resulted in higher systemic quercetin (QCT) exposure following oral administration. These pharmacokinetic results are preliminary, and additional studies with a fully validated bioanalytical method are necessary to verify the observed differences.
- Open Access
- 16 October 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 17 (1) , 155-167
Phytosome Technology: A Journey from Formulation Development to Industrial and Commercial Translation
Phytosome technology has transformed the delivery of plant-based bioactives by effectively addressing issues such as poor solubility, instability, and limited oral absorption. Unlike traditional lipid carriers, phytosomes form molecular complexes with phospholipids and phytoconstituents, thereby enhancing their interaction with cell membranes and enhancing systemic exposure. This review highlights the growing importance of phytosomes as advanced delivery systems and explores future opportunities to translate natural bioactives into proven medical solutions by connecting core formulation principles with emerging industrial and commercial trends. A comprehensive literature review was conducted, encompassing advances in phospholipid engineering, hybrid delivery systems, patented technologies, and commercially available phytosome products across pharmaceuticals, nutraceuticals, and cosmeceuticals. Over time, phytosome technology has evolved from merely improving bioavailability to a versatile platform with expanding uses in pharmaceuticals, nutraceuticals, and cosmeceuticals. Advances in phospholipid engineering and hybrid delivery systems have further broadened its therapeutic and industrial applications. The transition of phytosomes from research samples to patented technologies and commercially available products highlights their practical significance. Despite these advances, manufacturing and regulatory challenges, as well as clinical validation challenges, still affect their future growth. Phytosomes hold considerable promise as advanced delivery systems for translating natural bioactives into proven medical solutions.
- 16 October 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 17 (1) , 155-167
Open AccessPhytosome Technology: A Journey from Formulation Development to Industrial and Commercial Translation
Phytosome technology has transformed the delivery of plant-based bioactives by effectively addressing issues such as poor solubility, instability, and limited oral absorption. Unlike traditional lipid carriers, phytosomes form molecular complexes with phospholipids and phytoconstituents, thereby enhancing their interaction with cell membranes and enhancing systemic exposure. This review highlights the growing importance of phytosomes as advanced delivery systems and explores future opportunities to translate natural bioactives into proven medical solutions by connecting core formulation principles with emerging industrial and commercial trends. A comprehensive literature review was conducted, encompassing advances in phospholipid engineering, hybrid delivery systems, patented technologies, and commercially available phytosome products across pharmaceuticals, nutraceuticals, and cosmeceuticals. Over time, phytosome technology has evolved from merely improving bioavailability to a versatile platform with expanding uses in pharmaceuticals, nutraceuticals, and cosmeceuticals. Advances in phospholipid engineering and hybrid delivery systems have further broadened its therapeutic and industrial applications. The transition of phytosomes from research samples to patented technologies and commercially available products highlights their practical significance. Despite these advances, manufacturing and regulatory challenges, as well as clinical validation challenges, still affect their future growth. Phytosomes hold considerable promise as advanced delivery systems for translating natural bioactives into proven medical solutions.
- Open Access
- 29 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1232
Phytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation
Natural bioactive compounds, especially plant-derived phytoconstituents, have gained significant interest due to their structural diversity, multitarget pharmacological activities, and favourable safety profiles. Their pharmaceutical translation is often hindered by poor aqueous solubility, limited membrane permeability, chemical instability, extensive first-pass metabolism, and, therefore, low oral bioavailability. Phytosomes, which are molecular complexes of bioactive compounds with phospholipids, have emerged as a new, effective, lipid-based delivery platform that can overcome these biopharmaceutical limitations and improve solubility, membrane interactions, systemic exposure, and therapeutic efficacy. The present review critically analyses recent advancements in phytosomal drug delivery, from formulation development to clinical translation, focusing on molecular complexation mechanisms, formulation strategies, physicochemical characterisation, pharmacokinetic enhancement, therapeutic applications, and challenges in clinical translation. The current review combines pharmaceutical design principles with recent advances in quality-by-design (QbD), computational formulation optimisation, hybrid phytosomal systems, scalable manufacturing approaches, and targeted delivery strategies. In addition, prospects for the future extension of phospholipid complexation to bioactive compounds from marine organisms, fungi, microorganisms, and algae are discussed in relevance to the next-generation natural product therapeutics. The present review serves as an emerging link between the discovery of natural bioactive compounds and the development of clinically translatable phytosomal systems from a pharmaceutical perspective.
- 29 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1232
Open AccessPhytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation
Natural bioactive compounds, especially plant-derived phytoconstituents, have gained significant interest due to their structural diversity, multitarget pharmacological activities, and favourable safety profiles. Their pharmaceutical translation is often hindered by poor aqueous solubility, limited membrane permeability, chemical instability, extensive first-pass metabolism, and, therefore, low oral bioavailability. Phytosomes, which are molecular complexes of bioactive compounds with phospholipids, have emerged as a new, effective, lipid-based delivery platform that can overcome these biopharmaceutical limitations and improve solubility, membrane interactions, systemic exposure, and therapeutic efficacy. The present review critically analyses recent advancements in phytosomal drug delivery, from formulation development to clinical translation, focusing on molecular complexation mechanisms, formulation strategies, physicochemical characterisation, pharmacokinetic enhancement, therapeutic applications, and challenges in clinical translation. The current review combines pharmaceutical design principles with recent advances in quality-by-design (QbD), computational formulation optimisation, hybrid phytosomal systems, scalable manufacturing approaches, and targeted delivery strategies. In addition, prospects for the future extension of phospholipid complexation to bioactive compounds from marine organisms, fungi, microorganisms, and algae are discussed in relevance to the next-generation natural product therapeutics. The present review serves as an emerging link between the discovery of natural bioactive compounds and the development of clinically translatable phytosomal systems from a pharmaceutical perspective.
- 11 June 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-22
Multi-target Agents in Complex Diseases: From Design Principles to Therapeutic Applications
Introduction: Multifactorial complex diseases such as cancer, neurodegeneration, and infections are poorly treated with traditional single-target therapies because biological networks are redundant and adaptively resistant. Methods: A comprehensive literature review was conducted to investigate the theoretical basis, design approaches (pharmacophore linking, fusing, and merging), and clinical uses of multi-target agents using network pharmacology and systems biology. Results: Multi-kinase inhibitors (imatinib, sunitinib, cabozantinib) approved by the Food and Drug Administration have shown superior efficacy to traditional monotherapies due to multiple driver inhibition; dual acetylcholinesterase and Beta-site amyloid precursor protein cleaving enzyme 1 inhibitors show enhanced neuroprotective effects against Alzheimer's disease; and β-lactam/βlactamase inhibitor combinations address drug resistance. Artificial intelligence can accelerate target identification, and novel design technologies, such as fragment-based screening, can generate balanced polypharmacology. Discussion: Multi-target strategies are ideal for overcoming redundancy in biological networks and minimizing drug resistance. However, several issues remain, including the complexity of target selection, the need to achieve balanced efficacy across multiple targets, ADMET optimization, and regulatory hurdles. Emerging technologies, such as quantum computing, precision polypharmacology based on multiomics profiling, and digital health integration, could improve target selection and optimization. Conclusion: Multi-target agents are no longer constrained by single-target effects; however, issues of balanced potency, ADMET, and control still exist. The combination of AI, quantum computing, and precision polypharmacology may enable more effective multi-target interventions to address unmet demands in complex diseases.
- 11 June 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-22
Multi-target Agents in Complex Diseases: From Design Principles to Therapeutic Applications
Introduction: Multifactorial complex diseases such as cancer, neurodegeneration, and infections are poorly treated with traditional single-target therapies because biological networks are redundant and adaptively resistant. Methods: A comprehensive literature review was conducted to investigate the theoretical basis, design approaches (pharmacophore linking, fusing, and merging), and clinical uses of multi-target agents using network pharmacology and systems biology. Results: Multi-kinase inhibitors (imatinib, sunitinib, cabozantinib) approved by the Food and Drug Administration have shown superior efficacy to traditional monotherapies due to multiple driver inhibition; dual acetylcholinesterase and Beta-site amyloid precursor protein cleaving enzyme 1 inhibitors show enhanced neuroprotective effects against Alzheimer's disease; and β-lactam/βlactamase inhibitor combinations address drug resistance. Artificial intelligence can accelerate target identification, and novel design technologies, such as fragment-based screening, can generate balanced polypharmacology. Discussion: Multi-target strategies are ideal for overcoming redundancy in biological networks and minimizing drug resistance. However, several issues remain, including the complexity of target selection, the need to achieve balanced efficacy across multiple targets, ADMET optimization, and regulatory hurdles. Emerging technologies, such as quantum computing, precision polypharmacology based on multiomics profiling, and digital health integration, could improve target selection and optimization. Conclusion: Multi-target agents are no longer constrained by single-target effects; however, issues of balanced potency, ADMET, and control still exist. The combination of AI, quantum computing, and precision polypharmacology may enable more effective multi-target interventions to address unmet demands in complex diseases.
- Open Access
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 293-303
EXPLORING NEW MONOAMINO OXIDASE- A (MAO-A) SELECTIVE INHIBITORS FROM CUCURBITO PEPO: A VIRTUAL SCREENING, MOLECULAR DOCKING, MD SIMULATIONS AND ADMET ANALYSIS
Objective: This study aimed to identify potential Monoamine oxidase (MAO) inhibitors from Cucurbita pepo to address the increasing prevalence of neurological and neuropsychiatric disorders, such as stroke, Alzheimer's, Parkinson's, autism, migraines, and depression, by targeting key enzymes involved in neurotransmitter degradation. Methods: The study utilised molecular docking and pharmacological, physiological, and ADMET property analyses to screen compounds from Cucurbita pepo. Ten promising MAO inhibitors were shortlisted for further analysis. Extensive Molecular Dynamics (MD) simulations were conducted over 100 nanoseconds to assess the stability and dynamic behaviour within the MAO-A complex. Results: Based on molecular docking results, four shortlisted compounds were identified as potential MAO-A inhibitors. Atomic-level docking studies were used to explore the binding mechanisms of the phytoconstituents within the active site of the MAO-A enzyme. The binding free energies of these compounds ranged from-9.183 to-6.001 kcal/mol. Phytoconstituent Compound C1 had the highest binding affinity with a G score of-9.183 kcal/mol, followed by Compound C2 with a G score of-9.045 kcal/mol. MD simulations further confirmed that both C1 and C2 formed highly stable complexes with MAO-A, suggesting their potential as effective inhibitors. Conclusion: Compounds C1 and C2 from Cucurbita pepo show promise as stable and effective MAO-A inhibitors. Further experimental validation is required to confirm these findings and evaluate their therapeutic potential in treating neurological disorders.
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 293-303
Open AccessEXPLORING NEW MONOAMINO OXIDASE- A (MAO-A) SELECTIVE INHIBITORS FROM CUCURBITO PEPO: A VIRTUAL SCREENING, MOLECULAR DOCKING, MD SIMULATIONS AND ADMET ANALYSIS
Objective: This study aimed to identify potential Monoamine oxidase (MAO) inhibitors from Cucurbita pepo to address the increasing prevalence of neurological and neuropsychiatric disorders, such as stroke, Alzheimer's, Parkinson's, autism, migraines, and depression, by targeting key enzymes involved in neurotransmitter degradation. Methods: The study utilised molecular docking and pharmacological, physiological, and ADMET property analyses to screen compounds from Cucurbita pepo. Ten promising MAO inhibitors were shortlisted for further analysis. Extensive Molecular Dynamics (MD) simulations were conducted over 100 nanoseconds to assess the stability and dynamic behaviour within the MAO-A complex. Results: Based on molecular docking results, four shortlisted compounds were identified as potential MAO-A inhibitors. Atomic-level docking studies were used to explore the binding mechanisms of the phytoconstituents within the active site of the MAO-A enzyme. The binding free energies of these compounds ranged from-9.183 to-6.001 kcal/mol. Phytoconstituent Compound C1 had the highest binding affinity with a G score of-9.183 kcal/mol, followed by Compound C2 with a G score of-9.045 kcal/mol. MD simulations further confirmed that both C1 and C2 formed highly stable complexes with MAO-A, suggesting their potential as effective inhibitors. Conclusion: Compounds C1 and C2 from Cucurbita pepo show promise as stable and effective MAO-A inhibitors. Further experimental validation is required to confirm these findings and evaluate their therapeutic potential in treating neurological disorders.
- 12 September 2024
- Published by Springer Nature
- p. 243-269
Polymer-Based Carriers for Targeting Lymphatic System
- 12 September 2024
- Published by Springer Nature
- p. 243-269
Polymer-Based Carriers for Targeting Lymphatic System
- Open Access
- 8 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 574
Ultrasonically Fabricated Beta-Carotene Nanoemulsion: Optimization, Characterization and Evaluation of Combinatorial Effect with Quercetin on Streptozotocin-Induced Diabetic Rat Model
Diabetes mellitus (D.M.) is a metabolic disease that has affected over 500 million people globally. Bioactive compounds such as β-carotene and Quercetin have gained research interest for their potential antidiabetic properties, and bioactives have reported superior combinatorial effects in several ailments, including D.M. However, poor oral bioavailability has limited their potential application. Thus, the present study was focused on developing ultrasonically fabricated β-Carotene nanoemulsion (βC-NE) by employing capmul as the oil phase, Gelucire 44/14 as surfactant and Acconon MCM C8 as co-surfactant. The 3 factor- 3 level Box-Behnken design (BBD) was applied to optimise the βC-NE and study the impact of selected independent variables such as % Smix (5 to 9%), amplitude (20–30%) and sonication time (2.5–7.5 min) on responses including globule size (G.S.), poly dispersibility Index (PDI) and entrapment efficiency (E.E.). Further, the combinatorial effect of βC-NE with Quercetin Nanoemulsion (QU-NE) in the streptozotocin-induced diabetic rat model was evaluated. The results exhibited that 7% Smix at 25% amplitude for 5 min produced βC-NE with a droplet size of 153.1 ± 12.25 nm, 0.200 ± 0.04 PDI, and 73.25 ± 3.25% E.E. The βC-NE showed superior in-vivo bioavailability by 5.38 folds. The βC-NE, combined with QU-NE, exhibited potential therapeutic benefits in controlling body weight, blood sugar level, lipid levels, and tissue damage markers. Additionally, the pancreatic cells and hepatic cells were well protected. These results demonstrate the potential benefits of βC-NE and QU-NE in combination and recommend them as a substitute strategy for diabetes.
- 8 February 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 574
Open AccessUltrasonically Fabricated Beta-Carotene Nanoemulsion: Optimization, Characterization and Evaluation of Combinatorial Effect with Quercetin on Streptozotocin-Induced Diabetic Rat Model
Diabetes mellitus (D.M.) is a metabolic disease that has affected over 500 million people globally. Bioactive compounds such as β-carotene and Quercetin have gained research interest for their potential antidiabetic properties, and bioactives have reported superior combinatorial effects in several ailments, including D.M. However, poor oral bioavailability has limited their potential application. Thus, the present study was focused on developing ultrasonically fabricated β-Carotene nanoemulsion (βC-NE) by employing capmul as the oil phase, Gelucire 44/14 as surfactant and Acconon MCM C8 as co-surfactant. The 3 factor- 3 level Box-Behnken design (BBD) was applied to optimise the βC-NE and study the impact of selected independent variables such as % Smix (5 to 9%), amplitude (20–30%) and sonication time (2.5–7.5 min) on responses including globule size (G.S.), poly dispersibility Index (PDI) and entrapment efficiency (E.E.). Further, the combinatorial effect of βC-NE with Quercetin Nanoemulsion (QU-NE) in the streptozotocin-induced diabetic rat model was evaluated. The results exhibited that 7% Smix at 25% amplitude for 5 min produced βC-NE with a droplet size of 153.1 ± 12.25 nm, 0.200 ± 0.04 PDI, and 73.25 ± 3.25% E.E. The βC-NE showed superior in-vivo bioavailability by 5.38 folds. The βC-NE, combined with QU-NE, exhibited potential therapeutic benefits in controlling body weight, blood sugar level, lipid levels, and tissue damage markers. Additionally, the pancreatic cells and hepatic cells were well protected. These results demonstrate the potential benefits of βC-NE and QU-NE in combination and recommend them as a substitute strategy for diabetes.